UROLOGICAL LASER MANUFACTURERS CAN ADD BPH INDICATION VIA 510(K), FDA SAYS; PROTOCOLS FOR CLEARED DEVICES WITH PROSTATIC INDICATIONS DUE WITHIN 90 DAYS
This article was originally published in The Gray Sheet
Executive Summary
Premarket notification applications for medical lasers for the treatment of benign prostatic hyperplasia (BPH) require "limited confirmatory data" from clinical studies involving a minimum of 50 patients in both treatment and control groups and "using a matched cohort or randomized study design," FDA says in a draft guidance on study requirements needed to support 510(k)s for general use lasers with indications for prostatectomy and the treatment of BPH.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.